Literature DB >> 19883425

6th International Immunoglobulin Symposium: poster presentations.

E Fernandez-Cruz1, S V Kaveri, H-H Peter, A Durandy, N Cantoni, I Quinti, R Sorensen, J B Bussel, M G Danieli, A Winkelmann, J Bayry, F Käsermann, P Späth, M Helbert, A Salama, I N van Schaik, N Yuki.   

Abstract

The posters presented at the 6th International Immunoglobulin Symposium covered a wide range of fields and included both basic science and clinical research. From the abstracts accepted for poster presentation, 12 abstracts were selected for oral presentations in three parallel sessions on immunodeficiencies, autoimmunity and basic research. The immunodeficiency presentations dealt with novel, rare class-switch recombination (CSR) deficiencies, attenuation of adverse events following IVIg treatment, association of immunoglobulin (Ig)G trough levels and protection against acute infection in patients with X-linked agammaglobulinaemia (XLA) and common variable immunodeficiency (CVID), and the reduction of class-switched memory B cells in patients with specific antibody deficiency (SAD). The impact of intravenous immunoglobulin on fetal alloimmune thrombocytopenia, pregnancy and postpartum-related relapses in multiple sclerosis and refractory myositis, as well as experiences with subcutaneous immunoglobulin in patients with multi-focal motor neuropathy, were the topics presented in the autoimmunity session. The interaction of dendritic cell (DC)-SIGN and alpha2,6-sialylated IgG Fc and its impact on human DCs, the enrichment of sialylated IgG in plasma-derived IgG, as wells as prion surveillance and monitoring of anti-measles titres in immunoglobulin products, were covered in the basic science session. In summary, the presentations illustrated the breadth of immunoglobulin therapy usage and highlighted the progress that is being made in diverse areas of basic and clinical research, extending our understanding of the mechanisms of immunoglobulin action and contributing to improved patient care.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19883425      PMCID: PMC2801033          DOI: 10.1111/j.1365-2249.2009.04028.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

Review 1.  Adverse effects of intravenous immunoglobulin therapy.

Authors:  U E Nydegger; M Sturzenegger
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

2.  Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin.

Authors:  Jagadeesh Bayry; Sébastien Lacroix-Desmazes; Cedric Carbonneil; Namita Misra; Vladimira Donkova; Anastas Pashov; Alain Chevailler; Luc Mouthon; Bernard Weill; Patrick Bruneval; Michel D Kazatchkine; Srini V Kaveri
Journal:  Blood       Date:  2002-08-29       Impact factor: 22.113

3.  Intravenous administration of human gamma-globulin.

Authors:  S BARANDUN; P KISTLER; F JEUNET; H ISLIKER
Journal:  Vox Sang       Date:  1962       Impact factor: 2.144

4.  Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia.

Authors:  Richard L Berkowitz; E Anders Kolb; Janice G McFarland; Megan Wissert; Andrea Primani; Martin Lesser; James B Bussel
Journal:  Obstet Gynecol       Date:  2006-01       Impact factor: 7.661

Review 5.  Use of intravenous immunoglobulin G (IVIG).

Authors:  R John Looney; Jennifer Huggins
Journal:  Best Pract Res Clin Haematol       Date:  2006       Impact factor: 3.020

6.  DC-SIGN and alpha2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells.

Authors:  Jagadeesh Bayry; Kushagra Bansal; Michel D Kazatchkine; Srini V Kaveri
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

Review 7.  Immunoglobulin replacement therapy in primary antibody deficiency diseases--maximizing success.

Authors:  Anne Durandy; Volker Wahn; Steve Petteway; Erwin W Gelfand
Journal:  Int Arch Allergy Immunol       Date:  2005-02-15       Impact factor: 2.749

8.  Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.

Authors:  C Confavreux; M Hutchinson; M M Hours; P Cortinovis-Tourniaire; T Moreau
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

9.  Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse.

Authors:  Sandra Vukusic; Michael Hutchinson; Martine Hours; Thibault Moreau; Patricia Cortinovis-Tourniaire; Patrice Adeleine; Christian Confavreux
Journal:  Brain       Date:  2004-05-06       Impact factor: 13.501

10.  A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.

Authors:  M C Dalakas; I Illa; J M Dambrosia; S A Soueidan; D P Stein; C Otero; S T Dinsmore; S McCrosky
Journal:  N Engl J Med       Date:  1993-12-30       Impact factor: 91.245

View more
  3 in total

1.  Open-label study on treatment with 20 % subcutaneous IgG administration in polymyositis and dermatomyositis.

Authors:  Maria Giovanna Danieli; Romina Moretti; Simona Gambini; Luca Paolini; Armando Gabrielli
Journal:  Clin Rheumatol       Date:  2014-01-07       Impact factor: 2.980

Review 2.  Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy.

Authors:  S V Kaveri; M S Maddur; P Hegde; S Lacroix-Desmazes; J Bayry
Journal:  Clin Exp Immunol       Date:  2011-06       Impact factor: 4.330

3.  Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia.

Authors:  Theresa Guhr; Judith Bloem; Ninotska I L Derksen; Manfred Wuhrer; Anky H L Koenderman; Rob C Aalberse; Theo Rispens
Journal:  PLoS One       Date:  2011-06-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.